Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course



Similar documents
Title: Opening Plenary Session Challenges and Opportunities to Impact the Opioid Dependence Crisis

Web-Based Resources. Locating Treatment

Opiate Addiction in Ohio: An Update on Scope of Problem Ashland Ohio

Governor s Task Force on Mental Health and Substance Use.

John R. Kasich, Governor Orman Hall, Director

TREATMENT MODALITIES. May, 2013

The Heroin and Prescription Drug Abuse Prevention and Reduction Act Section by Section

The Federation of State Medical Boards 2013 Model Guidelines for Opioid Addiction Treatment in the Medical Office

Opioid Agonist Therapy: The Duration Dilemma Edwin A. Salsitz, MD, FASAM Mount Sinai Beth Israel, New York, NY March 10, 2015

IN THE GENERAL ASSEMBLY STATE OF. Ensuring Access to Medication Assisted Treatment Act

Objectives: Perform thorough assessment, and design and implement care plans on 12 or more seriously mentally ill addicted persons.

Treatment of opioid use disorders

Considerations in Medication Assisted Treatment of Opiate Dependence. Stephen A. Wyatt, D.O. Dept. of Psychiatry Middlesex Hospital Middletown, CT

Testimony of The New York City Department of Health and Mental Hygiene. before the

U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health

EPIDEMIOLOGY OF OPIATE USE

Prescriber Behavior, Pain Treatment and Addiction Treatment

Minimum Insurance Benefits for Patients with Opioid Use Disorder The Opioid Use Disorder Epidemic: The Evidence for Opioid Treatment:

Alcohol and Drug Abuse Treatment Centers

Opioid Prescribing for Chronic Pain: Guidelines for Marin County Clinicians

Confronting the Crisis of Opioid Addiction: An Overview of Beacon s White Paper

STATE PLAN TO PREVENT AND TREAT PRESCRIPTION DRUG ABUSE RECOMMENDATION SUMMARY Governor s Prescription Drug Abuse Prevention Council

Acronyms for the Prevention and Treatment of Substance Use Disorders. Prepared by Mental Health Legal Advisors Committee November 2015

Care Management Council submission date: August Contact Information

Addiction Psychiatry Fellowship Rotation Goals & Objectives

How To Treat Anorexic Addiction With Medication Assisted Treatment

Performance Standards

Buprenorphine Therapy in Addiction Treatment

MEDICATION ASSISTED TREATMENT FOR OPIOID ADDICTION

HOPE Helping Opiate- Addicted Pregnant women Evolve

Integrating Medication- Assisted Treatment (MAT) for Opioid Use Disorders into Behavioral and Physical Healthcare Settings

Presentation to Senate Health and Human Services Committee: Prescription Drug Abuse in Texas

Alcohol and Drug. A Cochrane Handbook. losief Abraha MD. Cristina Cusi MD. Regional Health Perugia

FISCAL IMPACT STATEMENT. LS 7351 NOTE PREPARED: Feb 6, 2015 BILL NUMBER: SB 464 BILL AMENDED: Feb 5, 2015

Death in the Suburbs: How Prescription Painkillers and Heroin Have Changed Treatment and Recovery

Opioid Treatment Services, Office-Based Opioid Treatment

Licensure of Substance Abuse Treatment Programs Required Amendments

Resources for the Prevention and Treatment of Substance Use Disorders

1) What would it take to get four or five FQHCs to implement ECHO, and how many patients can we serve?

Office-based Treatment of Opioid Dependence with Buprenorphine

Opioid/Opiate Dependent Pregnant Women

Opioid Addiction & Corrections

Increasing Access to Opioid Addiction Treatment

SEEKING DRUG ABUSE TREATMENT: KNOW WHAT TO ASK

Bsafe Blackpool Community Safety and Drugs Partnership. Drug and Alcohol treatment planning in the community for Young People and Adults 2012/13

Travis Baggett, MD, MPH Jessie M. Gaeta, MD Jennifer Brody, MD, MPH Boston Health Care for the Homeless Program

State Policies and Adoption of Buprenorphine: Summary Results of Telephone Interviews with State Agency Staff

Joel Millard, DSW, LCSW Dave Felt, LCSW

Opioid Addiction and Methadone: Myths and Misconceptions. Nicole Nakatsu WRHA Practice Development Pharmacist

MAT Counselor Education Course Exam Questions Packet Part 1

An integrated approach to addressing opiate abuse in Maine. Debra L. Brucker, MPA, PhD State of Maine Office of Substance Abuse October 2009

Section 303(g)(2)(G) of the Controlled Substances Act (21 U.S.C. 823(g)(2)(G)) is amended. (1) by striking clause (ii) and inserting the following:

Use of Pharmacotherapies by Substance Abuse Treatment Facilities

Reforming the Response To Substance Use: A Drug Policy for the 21 st Century

Washington State Interagency Opioid Working Plan

The Heroin and Opioid Epidemic in Northeast Ohio: One Year Report to the Community

The Changing Face of Opioid Addiction:

Treatment Approaches for Drug Addiction

Various therapies are used in the

Medication Assisted Treatment

A Drug Policy for the 21st Century. Office of National Drug Control Policy

Subject: Health; food and drugs; treatment of opiate addiction. Statement of purpose: This bill proposes to require the department 6of health to

MEDICAL POLICY Treatment of Opioid Dependence

ALABAMA BOARD OF MEDICAL EXAMINERS ADMINISTRATIVE CODE

ST. CLAIR COUNTY COMMUNITY MENTAL HEALTH Date Issued: 07/09 Date Revised: 09/11;03/13;06/14;07/15

Suboxone Programs: Treating Opioid Dependence in CHCs Andrew Putney, MD Medical Director SSTAR ATS and CHC, Fall River, Massachusetts

Alcohol and Prescription opiate abuse: Responsibilities of Stakeholders to reduce the problem. Thomas Kosten MD

Florida Alcohol and Drug Abuse Association. Presented to the Behavioral Health Quarterly Meeting Pensacola, Florida April 23, 2014

Traci C. Green, PhD, MSc Jody Rich, MD, MPH

Presentation to the Boston HIV Planning Council. Lydie Ultimo, MSW Director Bureau of Substance Abuse Services

Financial Disclosures

Behavioral Health Provider Implementation of Whole Health Integrative Treatment Services

BUPRENORPHINE TREATMENT

Opioids for Pain Treatment. Opioids for Chronic Pain and Addiction Treatment. Outline for Today. Opioids for pain treatment

Update on Buprenorphine: Induction and Ongoing Care

Transcription:

The American Association for the Treatment of Opioid Dependence, provider #1044, is approved as a provider for social work continuing education by the Association of Social Work Boards (ASWB) www.aswb.org, through the Approved Continuing Education ACE) program. The American Association for the Treatment of Opioid Dependence (AATOD) maintains responsibility for the program. ASWB Approval Period: 6/12/2013 6/12/2016. Social workers should contact their regulatory board to determine course approval. Social workers participating in this course will receive 36.75 (clinical or social work ethics) continuing education clock hours. PC1 - Pre-Conference Session Title: The Certified Medication Assisted Treatment Advocate (CMA) Training Course Discuss basic information regarding medication assisted treatment developed by the National Alliance for Medication Assisted Treatment (NAMA Recovery). Develop an understanding about the science of addiction Describe the laws behind methadone and buprenorphine treatment Identify basic tools to work as an advocate. Explain how advocacy and the media respond to each other and how to properly handle different situations. Identify ways to use advocacy to change policy. Analyze advocacy campaigns to target an issue or respond to negative and incorrect information about medication assisted treatment. Describe the basic ethics for being an advocate and types of advocacy including handling grievances, systems advocacy, education of policy makers and the community. Credit Hours: 8 PC2 - Pre-Conference Session Title: Buprenorphine and Office-Based Treatment of Opioid Dependence Identify goals of the course and discuss their relevance to opioid dependence. Discuss buprenorphine efficacy and safety. Identify legislative changes.

Describe patient selection. Demonstrate clinical use of buprenorphine. Discuss non-pharmacological interventions Discuss medical and psychiatric conditions in opioid dependent patients. Discuss special treatment populations. Demonstrate office procedures. Credit Hours: 8.5 PC3 - Pre-Conference Session Title: Opioid Dependence in Peri-Partum Women: Policy, Collaboration, and Strategy Identify collaborative partnerships necessary in developing a coordinated response between child welfare, substance abuse treatment, medication assisted treatment, family court and medical professionals. To identify promising practices being implemented to improve outcomes for women with opioid dependency and their infants exposed in utero. Describe effective strategies and technical assistance needed by pregnant and postpartum women treatment programs. PC4 - Pre-Conference Session Title: OTP Clinical Staff Education Workshop Define best clinical practice to reduce morbidity and mortality associated with methadone maintenance therapy (MMT) in opioid addiction patients. Identify the risks associated with use of methadone in MMT Describe the unique characteristics of methadone pharmacology and pharmacotherapy. Demonstrate opioid treatment program (OTP) patient screening, assessment, induction, stabilization and maintenance techniques in MMT.

Identify and address co-occurring medical/psychiatric disorders that are seen in opioid addicted patients. Design treatment services and levels of care for patients in MMT. Course Target Audience: Beginning & Intermediate Credit Hours: 7 PC5 - Pre-Conference Session Title: Nurses and Opioid Treatment Programs Define Best Practice Guidelines for nurses working in an opioid treatment program setting. Identify key practice recommendations pertaining to nurses role in Medication Assisted Treatment. Identify educational, organizational, and policy recommendations to create a supportive environment for nurses. Course Target Audience: Beginning & Intermediate PC6 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.

PC7 - Pre-Conference Session Title: New and emerging medications for the treatment of opioid use disorder Describe medications for treating opioid dependence and overdose. Compare and contrast the use of MAT and naltrexone for opioid dependence. Discuss the use of non-opioid medications for the treatment of opioid use disorder and its impact on treatment adherence. PC8 - Pre-Conference Session Title: Opioid Maintenance Pharmacotherapy: A Course for Clinicians Identify interest in the field of Medication Assisted Treatment (MAT) of opioid dependence. Identify best practices in MAT Describe and discuss current challenges and relevant case studies to facilitate understanding of didactic principles. Describe how to deliver safe and effective MAT for patients with opioid dependence. Credit Hours: 8.5 PC9 - Pre-Conference Session Title: Countering Opioid Stigma: Communicating Messages to Influence Public Perception Explain how negative public opinion and media affect the field and its ability to influence drug policy. Identify key messages designed to counter the stigma and stereotypes in opioid addiction and MAT. Describe effective communication techniques with media representatives about the treatment system.

PC10 - Pre-Conference Session Title: Intersection of Pain and Addiction: Research and Clinical Practice Describe the neuropsychobiology of pain and explain the need for multidimensional treatment in patients with co-morbid pain and opioid addiction. Identify specific issues related to acute and chronic pain in patients in opioid treatment programs. Identify effective assessment and treatment strategies for patients with co-morbid pain and opioid dependence. PC11 - Pre-Conference Session Title: State Opioid Treatment Authority Meeting Identify federal and state regulatory entities overseeing the use of medication assisted treatment (MAT). Identify best practices in providing oversight of MAT. Describe strategies to improve joint regulatory monitoring of OTPs. Identify strategies to promote joint oversight and compliance with established protocols in medication assisted treatment. Credit Hours: 8

PC12 - Pre-Conference Session Title: Opioid Treatment Program Accreditation Town Hall Meeting Identify and discuss new standards, initiatives & tools available through The Joint Commission. Describe how to implement updated or revised Joint Commission accreditation standards and explain how to access new tools & resources available through The Joint Commission. Develop a patient plan for care, treatment & services that is compliant with all related Joint Commission standards. PC13 - Pre-Conference Session Title: Recovery and Medication Assistance Treatment Identify principles that can be applied for individuals using medication in their recovery. Identify key factors in implementing a peer mentoring program. Describe important resources for organizations to access to improve patient care and assist in the recovery process.

PC14 - Pre-Conference Session Title: Managing Workplace Risks: Ten Things Employers Need to Known in 2015 to Avoid Workplace Legal Claim Identify employment litigation as it relates to OTPs. Describe how regulatory changes and state and federal case holdings affect the workforce. Describe risk reduction strategies for employers. Identify strategies to promote compliance with established protocols in medication assisted treatment. Course Target Audience: Advanced PC15 - Pre-Conference Session Title: OTP Liability for Patient-Related Motor Vehicle Accidents: A Mock Trial and Focus Group Presentation Identify the risk of opioid treatment programs (OTPs) liability for patients in medication assisted treatment. Develop knowledge about approved policies to treat chronic opioid addiction. Describe current regulations explained by judicial personnel working within the systems. PC16 - Pre-Conference Session Title: Presentation by the World Federation for the Treatment of Opioid Dependence Identify strategies implemented by patients who misuse opiates/opioids while in opioid maintenance treatment. Discuss measurable outcomes in opioid dependence care. Analyze the effects of agonist opioid treatment on sexual dysfunctions.

Identify strengths and limitations of replacement therapy method resettlement in prisons. Describe emerging trends in alternative routes for prescription drug misuse in Europe. Describe the utilization of motivational interviewing to facilitate 12 steps for opiate addiction. Explain existing and future treatments and prevention of hepatitis C. Identify factors associated with outcome of inpatient opioid addiction treatment. Identify risk factors for weight gain among patients in methadone maintenance treatment. Discuss the utilization of naloxone in an effort to prevent opioid overdose. Describe effectiveness of medications utilized in the treatment of opioid addiction. Describe the work of the World Federation for the Treatment of Opioid Dependence PC17 - Pre-Conference Session Title: Overdose Prevention Implementation Strategies Describe the significant need for both systemic and individual interventions for healthcare professionals and first responders to address opioid overdoses. Identify current evidence for the administration of naloxone to reverse opioid overdoses by bystanders. Describe steps in the utilization of naloxone to reverse opioid overdose.